17.06.20 Covid-19 Update



Update by Ministry of Health

For the second day running, Malta has registered six new cases, identified through 911 swabs. One of today’s cases is part of a known cluster, the Health Department said, which now includes 43 cases. The other five are sporadic, four of which were symptomatic.

With two persons recovering, the number of active cases has gone back above 40, while the country’s total tally now stands at 662.



Majority of people worry about financial future, survey finds

A survey on household money management has found that 55% of the population are worried about their financial future, with 19% saying that they worry about their financial prospects very much.

ĠEMMA, the government’s financial capability education platform, published its findings on research carried out between May 29 and June 5, based on 405 respondents, to gauge attitudes and perceptions towards personal finance in a COVID-19 context.

Overall, 83% of respondents said they felt in control of their financial situation, 41% that they always planned monthly expenditures and 28% that they sometimes planned.


Air Malta will operate flights to 22 destinations for summer 2020

After the closure for over three months of Malta’s International Airport for commercial operations, Air  Malta will commence its summer  schedule on  Wednesday 1st July, connecting Malta to 22 destinations within Europe, a company statement read.

Air Malta flights to Rome, Lyon and Marseille will now join the previously announced flights to Catania, Munich, Frankfurt, Berlin, Dusseldorf, Vienna, Zurich, Geneva, and Prague commencing on 1st July.


Coronavirus vaccine could be on market in mid-2021 – CureVac

A vaccine against the coronavirus pandemic by CureVac could be on the market in mid- 2021, the unlisted German company said on Wednesday.

CureVac might be able to apply for approval early next year, Klaus Cichutek, President of German vaccine regulator PEI, added during a joint videoconference.

Earlier, the unlisted German biotech firm CureVac was to become the second company to launch human trials of an experimental coronavirus vaccine in the country, Germany’s vaccines regulator said on Wednesday.

Reuters reported on Tuesday that the watchdog, the Paul Ehrlich Institut, would approve testing on humans of the experimental vaccine.

The clinical trial, is the second to be approved by Germany’s vaccines regulator, the Paul

Ehrlich Institute, after a trial by BioNTech that began in April.

The World Health Organization lists 11 experimental coronavirus vaccines as currently being tested on humans, according to a table posted on its website.

EU Corner – by Comuniq.EU

EU Commission launches European strategy for development of vaccines against COVID-19

The European Commission has launched a European strategy to accelerate the development, manufacturing and deployment of vaccines against COVID-19

In a statement, the Commission said that “an effective and safe vaccine against the virus is our best bet to achieve a permanent solution to the pandemic. Time is of the essence. Every month gained in finding such a vaccine saves lives, livelihoods and billions of euros. Today’s strategy proposes a joint EU approach and builds on the mandate received from EU health ministers.”

European Commission President Ursula von der Leyen said: “This is a moment for science and solidarity. Nothing is certain, but I am confident that we can mobilise the resources to find a vaccine to beat this virus once and for all. We must be ready to manufacture and deploy such a vaccine across Europe and the world. This vaccine will be a breakthrough in the fight against the coronavirus, and a testament to what partners can achieve when we put our minds, research and resources together. The European Union will do all in its power to ensure that all peoples of this world have access to a vaccine, irrespective of where they live.”

This daily update bulletin is being compiled for the Chamber of Advocates by CI Consulta from Corporate ID Group. CI Consulta delivers policy research and analysis, evaluations and impact assessments up to policy implementation and integration.